Skip to main content
. Author manuscript; available in PMC: 2019 Jul 29.
Published in final edited form as: Kidney Int. 2018 Nov;94(5):1002–1012. doi: 10.1016/j.kint.2018.08.011

Figure 11: Exogenous FGF23 does not alter primary osteoblast mineralization in vitro.

Figure 11:

Quantification of extracted Alizarin Red S dye from healthy control (closed bars) and pediatric dialysis patient (open bars) primary osteoblasts grown to confluence and cultured under standard pro-mineralizing conditions in the presence or absence of exogenous human FGF23 for 2 weeks. Values represent the mean ± standard error values for the 3 controls and 6 patients. The asterisk indicates a between-group difference in mineral accumulation.